Evidence map›Paper›PMID 41238838›Full record

ReviewNature chemical biology2026

Degrons and degradation signals beyond short linear motifs.

Baiyun Wang, Ning Zheng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Baiyun WangDepartment of Pharmacology, University of Washington, Seattle, WA, USA. bywang@uw.edu.ORCID 0000-0003-2489-817X
Ning ZhengDepartment of Pharmacology, University of Washington, Seattle, WA, USA. nzheng@uw.edu.ORCID 0000-0002-1039-1581

Funding

Structural Basis for Antiarrhythmic Drug ActionR01HL112808 · NHLBI · UNIVERSITY OF WASHINGTON · PI ZHENG, NING · 2012 to 2025
$7.8M
Regulation of Opioid Sensitivity and Tolerance by Ubiquitin Ligase SignalingR01DA056370 · NIDA · SEATTLE CHILDREN'S HOSPITAL · PI Brock Grill, NING ZHENG · 2022 to 2026
$3.1M
Structure and Mechanism of the SET1/COMPASS H3K4 Methyltransferase ComplexR01HD097408 · NICHD · UNIVERSITY OF WASHINGTON · PI CHATTERJEE, CHAMPAK, ZHENG, NING · 2020 to 2024
$1.9M
NICHD NIH HHS R01 HD097408NIDA NIH HHS R01 DA056370U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01HL112808
6 · The paper itself

Abstract

Ubiquitin-dependent protein degradation regulates myriad fundamental cellular processes. At its core are degradation signals, or degrons, that initiate substrate engagement and ubiquitination by E3 ubiquitin ligases. Here we highlight how a variety of degradation signals promote substrate-E3 ligase interactions to orchestrate protein turnover with precision. While short linear motifs are frequently identified as degrons, an increasing number of degrons have recently been mapped to high-order protein structures, underscoring the architectural diversity and cryptic nature of degradation signals. Furthermore, nonproteinaceous signals beyond degrons often facilitate the precise control of protein ubiquitination. These additional signals can reside within substrates and E3 ligases or at their interfaces. Finally, we discuss how dysregulation of degrons and degradation signals is linked to human diseases. A deeper mechanistic understanding of degradation signals will guide new therapeutic strategies, whether by restoring defective protein ubiquitination or by harnessing targeted protein degradation.

Indexed as

ProteinsProteolysisUbiquitin-Protein LigasesAmino Acid MotifsAnimalsDegronsHumansSignal TransductionUbiquitinUbiquitinationProteinsUbiquitinUbiquitin-Protein Ligases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.